MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from
at-the-market offering...
$7,614K
Net cash provided by
financing activities
$7,614K
Net increase
(decrease) in cash and cash...
$291K
Canceled cashflow
$7,323K
Stock-based compensation
expense
$2,299K
Value of shares issued
to consultants
$730K
Accrued liabilities
$249K
Non-cash lease expense
$73K
Depreciation of property and
equipment
$16K
Unrealized foreign
exchange loss
-$13K
Net cash used in
operating activities
-$7,293K
Effect of exchange rate
changes on cash and cash...
-$24K
Net cash used in
investing activities
-$6K
Canceled cashflow
$3,380K
Net loss
-$9,243K
Acquisition of property and
equipment
$6K
Accounts payable
-$813K
Other receivables
$388K
Prepaid expenses
$155K
Operating lease
liabilities
-$74K
Back
Back
Cash Flow
ONCOLYTICS BIOTECH INC (ONCY)
ONCOLYTICS BIOTECH INC (ONCY)
source: myfinsight.com